We use cookies to ensure our website works properly and to personalise your experience. Cookies policy
Sree Chaitanya Institute of Pharmaceutical Sciences, Karimnagar, Telangana, 505527
Antibiotic resistance represents a rapidly escalating global health threat that compromises the effective treatment of bacterial infections and challenges the sustainability of modern healthcare. This review critically examines the biological and molecular foundations of antibiotic resistance, emphasizing key mechanisms such as enzymatic antibiotic degradation, target site modification, reduced membrane permeability, active efflux systems, and biofilm-mediated tolerance. Recent emerging trends in resistance evolution, including the expansion of multidrug-resistant and extensively drug-resistant pathogens, the role of horizontal gene transfer, and the global dissemination of mobile genetic elements, are comprehensively discussed. Advances in genomic surveillance, resistome analysis, and artificial intelligence–assisted resistance prediction are highlighted as transformative tools for understanding resistance dynamics. By integrating mechanistic insights with contemporary epidemiological trends, this review provides a consolidated framework for interpreting the evolution and spread of antibiotic resistance. A deeper understanding of these processes is essential for guiding future research, informing policy development, and supporting the design of next-generation antimicrobial strategies.
An antibiotic is a chemical entity, either obtained naturally, semi-synthetically, or synthetically, that selectively inhibits the growth of or kills bacteria at low concentrations, facilitating the treatment and prevention of bacterial infections. Antibiotics impose their effects by targeting essential bacterial processes such as cell wall synthesis, protein synthesis, nucleic acid replication, or vital metabolic pathways, while generally exhibiting selective toxicity toward bacterial cells [1,2]. Antibiotic resistance (ABR) develops when bacteria undergo changes that reduce or remove the effectiveness of antibiotics that once controlled them. This process impairs years of medical progress, makes common infections increasingly difficult to manage, and raises the risk of severe illness and death worldwide [3]. The excessive misuse and overuse of antibiotics in human medicine, veterinary practice, and agriculture exert intense selective pressure, accelerating the emergence and dissemination of resistant strains across diverse ecological niches [4,5]. ABR is now regarded as one of the major public health threats of the 21st century because of increasing resistance rates, rising morbidity, and expanding geographic spread [3].
Fig 1: showing the development of antibiotic resistance in body
Recent global surveillance data illustrate the rapid escalation of antibiotic-resistant infections across diverse settings. A major analysis from the Global Burden of Bacterial Antimicrobial Resistance shows that bacterial antimicrobial resistance was responsible for over a million deaths annually and contributed to millions more between 1990 and 2021, with projections indicating a continued rise through 2050 in the absence of effective interventions [6]. Multidrug-resistant organisms not only compromise routine clinical therapy but also complicate preventive strategies in surgery, oncology, and intensive care medicine [4,7].
The World Health Organization’s Global Antibiotic Resistance Surveillance Report 2025, based on data from over 100 countries, found that in 2023 one in six laboratory-confirmed bacterial infections was resistant to standard antibiotic treatments, with resistance rising in more than 40% of monitored pathogen-antibiotic combinations from 2018 to 2023. This report highlighted regional disparities in resistance prevalence, in regions such as South-East Asia and the Eastern Mediterranean, up to one in three infections were resistant, while in parts of Africa, resistance to first-line treatments for bloodstream infections exceeded 70%. Such patterns demonstrate that ABR is a truly global phenomenon with severe consequences for healthcare systems, particularly where diagnostic and treatment resources are limited [8].
The clinical and economic impacts of ABR are profound. Resistant infections lead to longer hospital stays, increased healthcare costs, limited therapeutic options, and higher mortality rates compared to susceptible infections. Meta-analyses indicate that resistant infections are associated with a substantially higher risk of premature death and extended hospitalisation, further straining health services worldwide. Without coordinated global action, forecasts suggest that the mortality and economic toll of ABR will continue to escalate, potentially exceeding other major causes of death and imposing substantial burdens on both public health and economic development [6,8].
The serious nature of antibiotic resistance stems from its impact on the treatment of common infections. Conditions such as urinary tract infections, bloodstream infections, and respiratory diseases that were once routinely treatable are increasingly unresponsive to first-line antibiotics, forcing clinicians to rely on more toxic, expensive, or less accessible drugs. The seriousness of antibiotic resistance is further underscored by its global reach and the broad array of pathogens involved. Resistance has been recorded across essential bacterial species responsible for major infectious diseases including Escherichia coli, Klebsiella pneumoniae, and Staphylococcus aureus, llustrating that no region or pathogen group is immune. The increasing prevalence of resistant bacteria not only complicates clinical management but also jeopardizes essential medical interventions that depend on effective antibiotics, such as surgeries, chemotherapy, and care of premature infants. The urgency of the situation has prompted international health authorities to emphasize accelerated monitoring, improved antibiotic stewardship, and investment in novel therapies. Without timely and sustained action, antibiotic resistance is poised to escalate further, compromising global health security and undermining the foundational effectiveness of modern medicine [8].
Mechanism:
Here some of the mechanism how bacteria develop the resistance. They are
It represents one of the most powerful and clinically important mechanisms by which bacteria develop resistance to antibiotics, involving the production of specific enzymes that chemically destroy or structurally modify antimicrobial agents, thereby neutralizing their biological activity before they reach their cellular targets [9]. The best-studied example of this process is the production of β-lactamases, a diverse group of hydrolytic enzymes that cleave the β-lactam ring present in penicillins, cephalosporins, monobactams, and carbapenems, a structural component essential for inhibition of bacterial cell-wall synthesis. Once this ring is hydrolyzed, the antibiotic can no longer bind to penicillin-binding proteins, resulting in complete loss of antibacterial activity [10]. β-lactamases are classified into multiple molecular classes (A–D), including extended-spectrum β-lactamases and carbapenemases, many of which exhibit broad substrate profiles capable of inactivating multiple generations of β-lactam antibiotics. Some β-lactamases, particularly metallo-β-lactamases, utilize zinc ions within their active sites to activate water molecules that attack and open the β-lactam ring, further enhancing their catalytic efficiency and spectrum of activity [11].
In addition to hydrolysis, many bacteria employ antibiotic-modifying enzymes that chemically alter drugs through covalent modification rather than destruction [9]. This strategy is especially prominent for aminoglycoside antibiotics, where aminoglycoside-modifying enzymes catalyze acetylation, phosphorylation, or adenylation of specific hydroxyl or amino groups on the antibiotic molecule. These chemical modifications change the molecular charge, shape, and steric properties of the drug, preventing effective binding to the 30S ribosomal subunit and thereby abolishing inhibition of protein synthesis [12]. Similar modification reactions occur for other antibiotic classes; for example, chloramphenicol acetyltransferases add acetyl groups to chloramphenicol, macrolide esterases hydrolyze the macrolide lactone ring, and macrolide phosphotransferases phosphorylate macrolide antibiotics, all of which significantly reduce antimicrobial potency [9]. Fosfomycin resistance enzymes such as FosA catalyze the opening of the epoxide ring of fosfomycin using glutathione-dependent reactions, rendering the drug inactive [11].
A defining feature of enzymatic inactivation mechanisms is that the genes encoding these enzymes are frequently located on plasmids, integrons, or transposons, facilitating rapid horizontal gene transfer between bacteria and enabling swift dissemination of resistance across species and environments [9]. The accumulation of multiple inactivating enzymes within a single bacterial cell can confer simultaneous resistance to several antibiotic classes, contributing directly to the emergence of multidrug-resistant and extensively drug-resistant pathogens [9,10]. Consequently, enzymatic inactivation not only compromises the effectiveness of existing antibiotics but also drives the continual need for novel drugs and resistance-enzyme inhibitors, highlighting its central role in the global antibiotic resistance crisis [11].
It is a critical mechanism by which bacteria develop resistance to antibiotics, involving mutations in genes encoding the drug targets that reduce antibiotic binding while maintaining essential cellular functions. In Helicobacter pylori, high-level resistance to clarithromycin is strongly associated with point mutations in the 23S rRNA gene, particularly the A2143G substitution, which alters the ribosomal peptidyl-transferase loop and prevents drug binding to the 50S ribosomal subunit, leading to treatment failure in resistant clinical isolates [13]. Similarly, fluoroquinolone resistance arises through mutations in the quinolone-resistance-determining regions (QRDRs) of the gyrA gene, which encodes DNA gyrase; these mutations modify enzyme conformation and decrease drug binding, significantly increasing the minimum inhibitory concentration of levofloxacin and ciprofloxacin in clinical populations [14]. Another example is observed in Staphylococcus aureus, where missense mutations in the mecA gene encoding penicillin-binding protein PBP2a alter its active site, resulting in low affinity for β-lactam antibiotics such as methicillin and cefoxitin, thereby allowing continued peptidoglycan synthesis even in the presence of these drugs [15]. These target alterations are genetically stable, enabling resistant bacteria to survive antibiotic exposure without significant fitness cost, and are frequently detected in clinical isolates worldwide, highlighting their contribution to the global antibiotic resistance crisis. The evolution and dissemination of such mutations emphasize the urgent need for surveillance and the development of novel therapeutic strategies that can overcome these target-based resistance mechanisms [13,14,15].
Fig 2: Representing the various mechanism involved how bacteria gained resistance
In bacteria it is referred as the decrease in the ability of antibiotics to enter the bacterial cell due to changes in the bacterial envelope, particularly the outer membrane porin channels that normally allow uptake of hydrophilic drugs. This mechanism is especially significant in Gram-negative bacteria, where the outer membrane acts as an additional permeability barrier and limits the passage of many antibiotics into the periplasmic space or cytoplasm [16,17]. In Gram-negative organisms, hydrophilic antimicrobial agents such as β-lactams, fluoroquinolones, and other small drugs typically cross the outer membrane through porin proteins, which form water-filled channels. Reduced permeability arises when bacteria either downregulate the expression of these porins or mutate porin genes, leading to fewer functional channels or narrower pores that restrict antibiotic influx [16,18]. For example, in Escherichia coli, modulation of porin expression and conductance influences how effectively antibiotics like ciprofloxacin can penetrate the outer membrane, with lower porin permeability correlating with increased resistance [19]. Genetic changes that alter transcription factors regulating porin gene expression can also contribute to reduced permeability. In one study, a mutation in the OmpR transcriptional regulator reduced the expression of major porins in E. coli, resulting in significantly higher carbapenem resistance by lowering the entry of drugs such as meropenem into the cell [16]. Similarly, research on the porin PorB in Neisseria meningitidis demonstrated that a single point mutation in the porin eyelet significantly decreased the permeation of β-lactam antibiotics, directly linking structural porin alterations to diminished drug uptake and resistance [17].
These are membrane-bound transport proteins that bacteria use to actively expel antibiotics and other toxic compounds from the cytoplasm to the outside environment, thereby reducing the intracellular concentration of drugs below inhibitory levels and contributing to resistance. Unlike passive diffusion, efflux pump activity is an energy-dependent process driven either by proton motive force (in many Gram-negative systems) or ATP hydrolysis (in ABC transporters), allowing bacteria to rapidly eliminate structurally diverse antimicrobial agents before they reach their cellular target. Because many of these proteins recognize a broad range of substrates, efflux pumps often confer multidrug resistance (MDR) phenotypes, enabling a single pump to reduce susceptibility to multiple antibiotic classes simultaneously [18,20].
Fig 3: Illustrating the mechanism of bacterial efflux pumps
Efflux systems are highly conserved and widespread among both Gram-positive and Gram-negative bacteria, often encoded on the chromosome and regulated in response to environmental signals and antibiotic exposure. Major efflux pump families involved in antibiotic resistance include the Resistance-Nodulation-Division (RND) family, particularly important in Gram-negative pathogens, the Major Facilitator Superfamily (MFS), the Small Multidrug Resistance (SMR) family, the Multidrug and Toxic compound Extrusion (MATE) family, and ATP-Binding Cassette (ABC) transporters [20]. For example, in Mycobacterium tuberculosis, overexpression of specific efflux pump genes such as Rv0677c (MmpS5) and Rv0191 has been shown to correlate with enhanced rifampin resistance, and inhibition of these pumps with verapamil significantly reduced rifampin minimum inhibitory concentrations in clinical resistant isolates, demonstrating a direct functional role for efflux activity in mediating drug resistance. This evidence underscores that efflux pumps not only eliminate antibiotics but also work in concert with other resistance mechanisms, such as drug target mutations, to strengthen overall resistance phenotypes [21].
Efflux pumps also contribute to adaptive resistance during antibiotic exposure by rapidly upregulating transporter expression in the presence of sub-inhibitory drug concentrations. Their broad substrate specificity means that changes in efflux activity can affect susceptibility to diverse drug classes, including fluoroquinolones, β-lactams, tetracyclines, and rifamycins, making them central players in the development of multidrug resistance in clinically important pathogens. Because efflux pumps prevent intracellular accumulation of antibiotics even before other resistance mechanisms are established, they often represent an early and effective bacterial response to antimicrobial stress. Efflux systems are thus critical determinants of both intrinsic and acquired antibiotic resistance across bacterial species.
Given their significant role, efflux pumps are promising targets for efflux pump inhibitors (EPIs) that can be co-administered with antibiotics to restore drug efficacy. Recent research has explored EPIs that modulate pump expression or block transport activity, illustrating that downregulation of efflux gene expression can synergize with antibiotics to reduce resistance levels [21]. However, translation of EPIs into clinical practice remains challenging due to issues of specificity, toxicity, and pharmacokinetics. Nonetheless, understanding the structure, regulation, and substrate specificity of bacterial efflux pumps continues to be a high priority for the development of novel strategies to combat antibiotic resistance.
This is a complex bacterial survival strategy in which microorganisms adhere to surfaces and produce a self-generated extracellular polymeric substance (EPS) matrix, forming structured communities that exhibit enhanced resistance to antibiotics compared to free-living (planktonic) cells. In these biofilm communities, cells encased within the EPS matrix experience limited antibiotic penetration, meaning drugs often fail to reach bactericidal concentrations deep inside the biofilm, reducing their effectiveness [22]. The EPS matrix itself, composed of polysaccharides, proteins, and extracellular DNA (eDNA), acts as a physical and chemical barrier that impedes antimicrobial access and helps retain resistant subpopulations [22,23].
Inside biofilms, micro environmental gradients of nutrients and oxygen create zones of slow-growing or dormant cells that are less susceptible to antibiotics targeting active processes such as cell-wall synthesis or protein production, resulting in phenotypic tolerance to drugs [24]. Additionally, the close proximity of cells within the biofilm facilitates horizontal gene transfer (HGT) and increased mutation rates, enabling the rapid spread of antibiotic resistance genes among community members. Research on Pseudomonas aeruginosa and other clinically important pathogens has shown that biofilm-associated bacteria can survive antibiotic treatment that would eradicate corresponding planktonic cells, underscoring the role of biofilms in chronic and recalcitrant infections. Due to these protective and adaptive features, biofilms are a major factor in persistent infections and substantially contribute to the global challenge of antibiotic resistance [22,25].
It is a mechanism of antibiotic resistance in which bacteria circumvent the targeted metabolic step affected by an antibiotic by using alternative enzymes, transport systems, or metabolic routes, allowing them to sustain essential biosynthetic processes despite the drug’s inhibitory action. Rather than directly altering the drug’s target, bacteria acquire the ability to fulfill the same metabolic needs through a different biochemical route that the antibiotic does not block. This can occur through horizontal acquisition of new functional genes or through metabolic mutations that rewire cellular pathways to maintain growth under drug pressure.
A well-documented example is resistance to the antifolate antibiotic sulfamethoxazole (SMX), which inhibits bacterial folate biosynthesis. In Group A Streptococcus, a horizontally acquired energy-coupling factor (ECF) transporter S component gene (thfT) allows the bacterium to import reduced folate compounds from the host environment, bypassing the need for de novo folate synthesis that SMX blocks. As a result, even though sulfamethoxazole inhibits the folate pathway, the imported folate molecules satisfy the cell’s metabolic requirement for tetrahydrofolate, enabling survival and high-level resistance in host conditions where reduced folates are available [26]. This is a clear case of metabolic bypass via acquisition of a new transporter that supplies the downstream metabolite the antibiotic disrupts.
In addition to gene acquisition, metabolic mutations can create pathway-specific bottlenecks that alter the flow of metabolites in ways that reduce susceptibility to antibiotics. Large-scale mutagenesis studies in Escherichia coli revealed that mutations in metabolic genes involved in purine nucleotide biosynthesis or the respiratory chain can modestly increase resistance levels to β-lactams and aminoglycosides, demonstrating that changes in metabolic flux through alternative pathways can change antibiotic susceptibility even without direct target modification. Such metabolic adaptations effectively reroute or compensate for blocked pathways, diminishing drug impact [27].
It is a resistance mechanism in which bacteria synthesize excess quantities of the molecular target of an antibiotic, allowing essential cellular processes to continue even when a portion of the enzyme is inhibited by the drug. This mechanism reduces antibiotic effectiveness by functionally diluting the inhibitory capacity of the antimicrobial agent, since available drug molecules are insufficient to inactivate the large pool of target proteins. A well-documented example is resistance to the antifolate antibiotic trimethoprim, which targets dihydrofolate reductase (DHFR). Certain Escherichia coli strains exhibit massive overproduction of DHFR, often caused by promoter mutations or gene amplification, resulting in high-level trimethoprim resistance while retaining an unaltered drug-binding site [28]. Similarly, gene amplification events involving antibiotic target genes or associated metabolic pathway genes have been shown to increase enzyme abundance, enabling bacteria to tolerate otherwise inhibitory drug concentrations [29]. Such amplifications provide a rapid adaptive response under antibiotic selective pressure and can be unstable yet highly effective during treatment.
Prodrugs are pharmacologically inactive compounds that require enzymatic conversion within bacterial cells into active antimicrobial agents; failure of this activation represents a significant mechanism of resistance. In several clinically important antibiotics, inability to bioactivate the prodrug effectively negates the antimicrobial effect. For example, isoniazid (INH), a frontline anti-tubercular agent, must be activated by the Mycobacterium tuberculosis catalase-peroxidase KatG. Mutations in katG, particularly S315T, significantly reduce prodrug activation, a principal driver of high-level INH resistance in global clinical isolates [30]. Additionally, other first- and second-line anti-tubercular prodrugs such as ethionamide, pyrazinamide, delamanid, and pretomanid similarly rely on specific activating enzymes; loss-of-function mutations in these pathways confer resistance without altering the target site [31].
Fig 4: Showing the how prodrug works in normal cell body verses resistant cell
Beyond tuberculosis, nitroimidazole antibiotics, used against anaerobic bacteria, require reduction by bacterial reductases; diminished expression or activity of these enzymes impairs prodrug activation and contributes to clinical resistance. Mathematical modeling further supports that prodrug failure can arise when bacterial growth outpaces activation kinetics or when mutations diminish enzyme catalytic efficiency, tipping the balance toward treatment escape [32]. Resistant strains may also exhibit altered enzyme expression, promoter mutations, or structural alterations that prevent bioactivation.
Because many activating enzymes are nonessential for bacterial viability, the mutational target size for resistance is large, facilitating evolution of activation-deficient mutants. Understanding these mechanisms is vital for diagnostics, stewardship, and designing next-generation prodrugs or direct-acting analogues that circumvent activation-based resistance.
It is a distinct and increasingly recognized mechanism by which bacteria evade the action of antibiotics. In this strategy, resistance proteins bind directly to the antibiotic’s target site or closely interact with it to prevent inhibitory binding, effectively “protecting” essential cellular machinery without altering the target structure itself [33,34].
One of the best-characterized examples is ribosomal protection proteins (RPPs) such as Tet(M) and Tet(O), which confer resistance to tetracycline antibiotics. These proteins interact with the bacterial ribosome and displace bound antibiotic molecules from their binding sites on the 16S rRNA, thereby restoring normal translation and preventing antibiotic rebinding [33,35]. Another major group of target protection factors is the ATP-binding cassette F (ABC-F) proteins, a family of ribosome-associated proteins that mediate resistance to a broad spectrum of translation-inhibiting antibiotics (e.g., macrolides, lincosamides, oxazolidinones). ABC-F proteins engage the ribosome and prompt dissociation of bound antibiotics, rescuing protein synthesis in the presence of drug pressure [36].
In addition to ribosomal systems, other target protection proteins include FusB-type factors, which protect elongation factor G (EF-G) from inhibition by fusidic acid through direct interaction, allowing translocation to proceed despite the presence of the antibiotic [34]. Similarly, plasmid-mediated Qnr proteins protect DNA gyrase and topoisomerase IV from quinolone binding by mimicking DNA and competitively preventing drug interaction with its targets [33].
The dissemination of antibiotic resistance is strongly driven by the acquisition of resistance genes through horizontal gene transfer (HGT), a process that allows bacteria to obtain functional resistance determinants from external sources. Unlike chromosomal mutation, HGT enables rapid adaptation by introducing fully developed resistance genes into susceptible populations, even across species boundaries [37,38].
Resistance genes are commonly associated with mobile genetic elements (MGEs) such as plasmids, transposons, integrons, and integrative conjugative elements. These platforms facilitate gene capture, rearrangement, and mobilization, allowing multiple resistance determinants to accumulate within a single genetic unit. Conjugative plasmids represent the most efficient vehicles for intercellular transfer, whereas transformation and bacteriophage-mediated transduction further contribute to genetic exchange [38,39].
The acquisition of MGEs often results in co-selection, whereby exposure to one antibiotic maintains resistance to several unrelated drug classes. Recent genomic studies indicate that environments subjected to intense antimicrobial pressure, such as healthcare settings and wastewater ecosystems serve as important reservoirs for resistance gene exchange. In addition, compatibility between donor and recipient bacteria influences successful integration and stable maintenance of acquired genes [40].
Emerging Trends:
Emerging trends in antibiotic resistance reflect the rapid and multifaceted evolution of resistant pathogens and transformative advances in detection, therapeutic approaches, and global epidemiology that are reshaping clinical practice and public health priorities. Recent surveillance data indicate that antibiotic resistance is not only increasing in prevalence but also expanding into previously treatable infections. The World Health Organization’s Global Antibiotic Resistance Surveillance Report 2025 demonstrates a significant rise in resistance across multiple pathogen antibiotic combinations globally, with data from 104 countries showing increased resistance in key pathogens responsible for common infections (e.g., bloodstream, urinary, and gastrointestinal infections). This trend underscores a narrowing window for effective treatment with existing antibiotics and the urgent need for novel strategies for mitigation and therapy [8].
A notable emerging trend is the dissemination of advanced resistance mechanisms against both older and newly approved antibiotics. Bacterial pathogens deploy a diverse repertoire of resistance strategies, including enzymatic inactivation, altered target sites, and increased efflux, but recent studies have identified novel proteins and enzymes facilitating resistance that had previously been underappreciated, thereby broadening the spectrum of resistance phenotypes encountered in clinical and community settings [11]. Moreover, analyses of newly approved antibiotics, such as β-lactam/β-lactamase inhibitor combinations and novel tetracycline derivatives, reveal that even these agents are already encountering resistance through adaptive bacterial responses, emphasizing the dynamic nature of AMR evolution and the need for continual drug innovation [41].
The horizontal transfer of resistance genes via mobile genetic elements remains a central driver of emerging resistance patterns. Recent genomic studies have revealed that not only traditional plasmids but also phage-plasmids contribute to the spread of antibiotic resistance genes across diverse bacterial populations, facilitating rapid gene flow and diversification even in the absence of selective antibiotic pressure [42]. Additionally, comprehensive genomic mapping of Staphylococcus aureus isolates has identified expanding reservoirs of resistance genes, indicating that both healthcare-associated and community strains are becoming increasingly adept at acquiring and maintaining resistance determinants [43].
Another trend involves the integration of advanced diagnostics and bioinformatics tools into AMR surveillance and clinical decision-making. Cutting-edge molecular methods, such as rapid sequencing and nanotechnology-enhanced detection platforms, are improving the ability to detect resistance phenotypes and genotypes in real time, thus enabling more precise antibiotic stewardship and targeted therapy [44]. Additionally, there is increasing recognition of the role of travel-related dissemination of resistant organisms, particularly multidrug-resistant Enterobacterales exhibiting colistin resistance, highlighting the interconnectedness of AMR as a global health issue [45]. Parallel to these biological and diagnostic trends are innovations in therapeutic paradigms aimed at counteracting resistance. Alternative strategies including bacteriophage therapy, which has shown promise against multidrug-resistant Acinetobacter baumannii, and computational approaches such as machine learning–guided antibiotic discovery offer complementary approaches to conventional antibiotics and may help bridge the gap between rising resistance and a slowing antibiotic pipeline [46].
Role of Artificial Intelligence (AI) in antibiotic resistance:
Artificial intelligence (AI) is increasingly recognized as a transformative tool in addressing antibiotic resistance (AR) by enabling data-driven insights across surveillance, diagnostics, drug discovery, and antimicrobial stewardship. Traditional approaches to managing AR are limited by the complexity and scale of microbiological, clinical, and genomic data; AI overcomes these constraints by integrating and analyzing large, heterogeneous datasets to support precision decision-making. One of the most impactful applications of AI lies in antibiotic discovery and development. Machine learning models trained on chemical structures and biological activity data have successfully identified novel antimicrobial compounds with unique mechanisms of action, exemplified by the discovery of halicin, a structurally distinct antibiotic active against multidrug-resistant pathogens [47]. AI-driven drug discovery accelerates screening processes, reduces development costs, and expands the antibiotic pipeline at a time when traditional discovery has stagnated.
AI also plays a critical role in predicting antimicrobial resistance patterns. By analyzing genomic sequences, transcriptomic profiles, and electronic health records, AI algorithms can accurately predict resistance phenotypes and forecast emerging resistance trends before they become clinically evident [48,49]. These predictive capabilities enhance real-time surveillance and enable early intervention strategies at both institutional and population levels. In clinical practice, AI supports rapid diagnostics and personalized antimicrobial therapy. Deep learning models integrated with laboratory and clinical data can assist in early pathogen identification, antimicrobial susceptibility prediction, and optimization of empirical therapy, thereby reducing inappropriate broad-spectrum antibiotic use a key driver of resistance [50]. Such systems enhance antimicrobial stewardship by guiding clinicians toward targeted, evidence-based prescribing.
From a public health perspective, AI facilitates large-scale resistance monitoring and outbreak detection, supporting global surveillance networks and One Health initiatives. By linking human, animal, and environmental data streams, AI contributes to a more comprehensive understanding of resistance transmission dynamics and informs policy development [51].
Recent developments in antibiotic resistance management:
As traditional antibiotics face diminishing efficacy due to rapid bacterial evolution, “smart antibiotics” and other innovative antimicrobial strategies are emerging to manage antibiotic resistance beyond conventional stewardship. Smart antibiotics are engineered to selectively target pathogenic bacteria while sparing beneficial microbiota, thereby reducing collateral damage and potentially slowing the development of resistance. For example, novel compounds like lolamicin have been designed to selectively inhibit specific bacterial transport systems, disrupting essential processes in Gram-negative pathogens while leaving commensal bacteria relatively unaffected, representing a microbiome-sparing approach that differs fundamentally from broad-spectrum antibiotics. This specificity may reduce off-target effects and resistance pressures by minimizing unnecessary microbial killing [52].
Beyond smart antibiotics, a suite of next-generation therapeutic and technological approaches are being investigated to counteract resistant pathogens. Bacteriophage therapy, which uses viruses that infect and lyse specific bacteria, is re-emerging as a precision treatment for infections caused by multidrug-resistant organisms; engineered phages and phage cocktails can be tailored to individual pathogens and can disrupt biofilms that typical antibiotics struggle to penetrate [53]. Antimicrobial peptides (AMPs), either natural or synthetic, act by disrupting bacterial membranes and cellular processes and have broad-spectrum activity with lower susceptibility to existing resistance mechanisms [54]. CRISPR-Cas-based antimicrobials offer sequence-specific targeting of resistance genes, enabling direct removal or inactivation of resistance determinants within bacterial genomes and facilitating the development of highly precise antibacterials with reduced impact on non-target microbes [55].
Nanotechnology-based approaches provide another promising avenue by enhancing drug delivery, overcoming bacterial defense mechanisms, and achieving high local drug concentrations at infection sites; functionalized nanoparticles can facilitate uptake of antibiotics into resistant bacteria or disrupt biofilms, expanding therapeutic options [56]. Additionally, quorum sensing interference and biofilm-disrupting agents target microbial communication and community behavior to attenuate virulence and increase susceptibility to antimicrobials [54].
Impact of antimicrobial stewardship on patient and public health:
Antimicrobial stewardship refers to a coordinated set of strategies designed to optimize the use of antimicrobial agents with the aim of improving patient outcomes, ensuring cost-effective therapy, and minimizing adverse consequences associated with antimicrobial use, particularly the development of antibiotic resistance.
The Infectious Diseases Society of America (IDSA) defines antimicrobial stewardship as Interventions designed to improve and measure the appropriate use of antimicrobial agents by promoting the selection of the optimal antimicrobial drug regimen, dose, duration of therapy, and route of administration. At its core, antimicrobial stewardship seeks to achieve the right antibiotic, at the right dose, by the right route, for the right duration, while balancing individual patient needs with broader public health responsibilities. Stewardship is therefore both a clinical quality initiative and a public health intervention, addressing antibiotic misuse that drives antimicrobial resistance at local, national, and global levels [57].
Antimicrobial stewardship programs should be established as institution-wide, multidisciplinary initiatives with strong leadership support. International guidelines recommend stewardship teams led by an infectious disease physician or trained clinician and a clinical pharmacist, with collaboration from microbiologists, infection prevention specialists, and information technology services. At the national level, health authorities integrate stewardship into antimicrobial resistance action plans, surveillance systems, and regulatory policies. Global organizations such as the World Health Organization and the Centers for Disease Control and Prevention provide standardized frameworks and technical guidance to support consistent implementation of stewardship across healthcare settings, ensuring sustainable optimization of antimicrobial use [57,58].
Antimicrobial stewardship programs (ASPs) have emerged as a transformative intervention in addressing the antibiotic resistance crisis by optimizing antimicrobial use while simultaneously improving patient safety and public health outcomes. At the patient level, stewardship interventions significantly reduce inappropriate antibiotic prescribing, including unnecessary initiation, excessive duration, and misuse of broad-spectrum agents. Meta-analyses and large observational studies consistently demonstrate that ASP implementation leads to a reduction in total antibiotic consumption without increasing mortality, treatment failure, or length of hospital stay, thereby reinforcing the clinical safety of stewardship-guided therapy [59,60].
A major patient-centered benefit of antimicrobial stewardship is the reduction in antibiotic-associated adverse events, particularly Clostridioides difficile infection and drug-related toxicities. Rational antibiotic selection and early de-escalation minimize disruption of normal microbiota and lower the incidence of secondary infections, translating into improved clinical outcomes and quality of care [61]. These effects are especially pronounced in high-risk populations such as critically ill patients, older adults, and those with chronic comorbidities.
From a public health perspective, ASPs exert a profound influence by reducing selective pressure for resistance development and transmission. Population-level studies have shown that sustained stewardship interventions are associated with improved antimicrobial susceptibility patterns and decreased prevalence of multidrug-resistant organisms across healthcare settings [60,62]. By curbing unnecessary antibiotic exposure, stewardship programs help preserve the effectiveness of existing antimicrobials, thereby extending their utility for future generations. The economic impact of antimicrobial stewardship further underscores its transformative role. Stewardship-driven reductions in antimicrobial use result in significant cost savings through decreased drug expenditure, shorter hospital stays, and lower infection-related complications. These benefits enhance healthcare system sustainability, particularly in resource-limited settings disproportionately affected by antimicrobial resistance [63].
A critical enabler of stewardship success is the integration of clinical pharmacists into multidisciplinary ASP teams. Pharmacist-led interventions, including prospective audit and feedback, dose optimization, therapeutic drug monitoring, and prescriber education have been shown to significantly reduce days of therapy and improve adherence to treatment guidelines [64,65]. Clinical pharmacists serve as key agents of change, translating stewardship principles into daily clinical practice while reinforcing patient-centered and evidence-based care.
Impact of clinical pharmacist on patients and public health:
Clinical pharmacists play a pivotal and transformative role in combating antibiotic resistance by acting at the interface between evidence-based guidelines, prescriber behavior, and patient care. Their integration into antimicrobial stewardship programs (ASPs) has significantly reshaped antibiotic prescribing practices, leading to measurable improvements in both individual patient outcomes and population-level public health indicators.
At the patient level, clinical pharmacists contribute directly to optimization of antimicrobial therapy through activities such as dose individualization, therapeutic drug monitoring, de-escalation of broad-spectrum antibiotics, and prevention of drug–drug interactions. Multiple studies demonstrate that pharmacist-led stewardship interventions significantly reduce inappropriate antibiotic use, duration of therapy, and antimicrobial-related adverse events without compromising clinical efficacy [64,65]. These interventions translate into lower rates of toxicity, reduced incidence of Clostridioides difficile infection, and improved treatment success, particularly in critically ill and vulnerable patient populations.
Clinical pharmacists also enhance timeliness and accuracy of antimicrobial therapy, ensuring early initiation of appropriate treatment and prompt modification based on microbiological data. Their involvement in prospective audit and feedback has been shown to improve adherence to clinical guidelines, shorten hospital length of stay, and reduce mortality associated with severe infections such as sepsis [66]. By bridging gaps between laboratory results and clinical decision-making, pharmacists enable precision-based antimicrobial use.
From a public health perspective, the impact of clinical pharmacists extends beyond individual patients to containment of antimicrobial resistance at the community and healthcare-system levels. By reducing unnecessary antibiotic exposure, pharmacist-driven stewardship lowers selective pressure for resistant organisms and contributes to improved institutional resistance patterns over time [57]. These effects support broader public health goals, including preservation of antimicrobial effectiveness, reduced transmission of multidrug-resistant organisms, and mitigation of healthcare-associated infections.
Economic benefits further underscore the public health value of clinical pharmacists. Pharmacist-led ASPs are consistently associated with significant cost savings, achieved through reduced antimicrobial expenditure, fewer infection-related complications, and optimized resource utilization [63]. Such economic efficiencies are critical for sustaining healthcare systems, particularly in low- and middle-income countries where the burden of antibiotic resistance is disproportionately high. Importantly, clinical pharmacists also function as educators and advocates for rational antibiotic use. Through direct prescriber engagement, protocol development, and patient education, pharmacists promote long-term behavioral change in antibiotic prescribing and consumption patterns. This educational role strengthens public awareness and supports national and global antimicrobial resistance action plans [67].
Post COVID influence on antibiotic resistance:
The COVID-19 pandemic has had a profound and lasting impact on global antibiotic prescribing practices, with significant implications for the acceleration of antimicrobial resistance (AMR). Despite COVID-19 being a viral illness, antibiotics were extensively prescribed during the pandemic, particularly among hospitalized and critically ill patients. Global estimates indicate that bacterial co-infections were present in fewer than 10% of COVID-19 cases, yet up to 70–75 % of hospitalized patients received at least one antibiotic, largely as empirical therapy. This disproportionate use created substantial selective pressure favoring the emergence and spread of resistant pathogens [68].
Broad-spectrum antibiotics, including third-generation cephalosporins, fluoroquinolones, carbapenems, and macrolides such as azithromycin, were frequently utilized during pandemic surges [69]. Such agents belong predominantly to the WHO “Watch” and “Reserve” categories and are known drivers of resistance when used indiscriminately. In many regions, antibiotic consumption remained elevated even after the acute pandemic phase, reflecting a persistent shift in prescribing behavior influenced by diagnostic uncertainty and fear of secondary infections [70]. Several epidemiological studies have demonstrated measurable increases in resistance rates during and after the pandemic. Retrospective analyses from hospital settings reported a rise in multidrug-resistant (MDR) and extensively drug-resistant (XDR) organisms, particularly Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus [71,72]. These trends were most pronounced in intensive care units, where prolonged hospital stays, invasive procedures, and high antimicrobial exposure created optimal conditions for resistance selection.
International cohort studies further revealed marked increases in the use of last-line antibiotics during COVID-19 waves across multiple countries, underscoring the global nature of this phenomenon [73]. Meta-analyses conducted in low- and middle-income countries highlighted an alarming coexistence of excessive antibiotic prescribing and limited antimicrobial stewardship infrastructure, amplifying the risk of resistance dissemination in resource-constrained settings [74].
Conversely, healthcare systems with robust antimicrobial stewardship programs demonstrated more controlled antibiotic use during the pandemic, with some institutions reporting reductions in overall consumption and stabilization of resistance rates [75]. In community and primary care settings, antibiotic prescribing initially declined during lockdown periods but later rebounded, particularly for respiratory tract infections, raising concerns about long-term resistance trends outside hospital environments [76]. Overall, the post-pandemic era represents a critical inflection point in the global AMR trajectory. The legacy of widespread empirical antibiotic use during COVID-19 has reinforced the urgency of strengthening antimicrobial stewardship, improving rapid diagnostic capacity, and integrating clinical pharmacists into pandemic preparedness frameworks. Without targeted interventions, the indirect consequences of the pandemic may continue to undermine the effectiveness of existing antibiotics and compromise patient and public health outcomes worldwide [77].
Behavioural and prescribing psychology in antibiotic resistance:
Behavioral and psychological factors play a critical yet often underappreciated role in inappropriate antibiotic prescribing and the subsequent emergence of antimicrobial resistance (AMR). While resistance is frequently discussed in microbiological or pharmacological terms, prescribing decisions are fundamentally human behaviors influenced by cognitive biases, social pressures, risk perception, and systemic constraints [78]. These behavioral determinants operate across healthcare settings and significantly shape antibiotic use patterns at both individual and population levels.
One of the most prominent psychological drivers of antibiotic overuse is diagnostic uncertainty. In the absence of rapid and definitive diagnostic tools, clinicians may prescribe antibiotics empirically to minimize the perceived risk of missing a bacterial infection, even when clinical evidence suggests a viral etiology [79]. This “better safe than sorry” approach is particularly common in emergency departments and primary care, where time pressure and limited follow-up amplify uncertainty. Fear of clinical deterioration and potential medico-legal consequences further reinforce defensive prescribing behaviors [80].
Cognitive biases also strongly influence antibiotic decision-making. Availability bias, where recent experiences with severe bacterial infections disproportionately affect prescribing choices, can lead clinicians to overestimate the likelihood of bacterial disease [81]. Similarly, action bias encourages intervention even when watchful waiting may be clinically appropriate because prescribing antibiotics is perceived as “doing something” rather than withholding treatment. Such biases contribute to the persistent gap between guideline recommendations and real-world practice. Patient-related behavioral factors exert additional pressure on prescribing decisions. Patient expectations for antibiotics, particularly in the treatment of respiratory tract infections, are well documented and can significantly increase the likelihood of antibiotic prescriptions [82]. Clinicians may acquiesce to these expectations to maintain patient satisfaction, avoid conflict, or reduce consultation time. In many cultural contexts, antibiotics are viewed as powerful, fast-acting remedies, reinforcing demand even when unnecessary [83].
Prescribing psychology is also shaped by social and institutional norms. Junior clinicians frequently mirror the prescribing habits of senior colleagues, perpetuating entrenched practices that may not align with evidence-based guidelines [84]. In hospital settings, hierarchical structures and fragmented care transitions can diffuse accountability, making it difficult to challenge inappropriate antibiotic use. In community settings, over-the-counter access to antibiotics and self-medication practices further normalize misuse and undermine stewardship efforts [85].
The COVID-19 pandemic magnified many of these behavioral drivers. Heightened uncertainty, fear of secondary infections, and unprecedented clinical pressure led to widespread empirical antibiotic use, even in settings with established stewardship programs [86]. This experience underscores how psychological stressors and crisis conditions can rapidly erode rational prescribing behaviors. Addressing behavioral and prescribing psychology is therefore essential for effective antimicrobial stewardship. Interventions such as audit and feedback, peer comparison, delayed prescribing strategies, and behavioral “nudges” have demonstrated success in improving prescribing practices [87]. Clinical pharmacists play a pivotal role in these interventions by providing real-time decision support, reinforcing guideline adherence, and facilitating shared decision-making with both clinicians and patients. Integrating behavioral science into stewardship programs represents a critical step toward sustainable antibiotic use and long-term resistance containment.
Future directions and research priorities in antibiotic resistance:
The accelerating global burden of antibiotic resistance (AR) demands a future-oriented research agenda that transcends traditional antimicrobial discovery and isolated stewardship efforts. Recent evidence highlights that sustainable resistance control will require integrated approaches combining innovation in diagnostics and therapeutics, implementation science, behavioral research, and global health equity [88].
A central research priority is the optimization of antimicrobial stewardship through implementation science. Although stewardship programs are widely endorsed, their effectiveness remains inconsistent across healthcare settings [89]. Future research should focus on identifying adaptable, context-specific stewardship models, particularly in low- and middle-income countries (LMICs), where infrastructure limitations and workforce shortages persist. Evaluating pharmacist-led, tele-stewardship, and digitally enabled interventions represents a critical area for scalable and cost-effective solutions [90].
Advances in diagnostic technologies are equally essential. Diagnostic uncertainty continues to drive empirical antibiotic prescribing, particularly in acute care and primary care settings. Research priorities include the development of rapid point-of-care diagnostics, host-response biomarkers, and molecular platforms that enable early pathogen identification and antimicrobial susceptibility prediction [91,92]. Implementation studies assessing how diagnostic stewardship can be effectively embedded into clinical workflows supported by clinical pharmacists are urgently needed to translate diagnostic innovation into meaningful prescribing change.
Revitalizing the antibiotic development pipeline remains a major global challenge. Despite rising resistance, the approval of novel antibiotics remains limited. Future research must prioritize non-traditional therapeutic strategies, including bacteriophage therapy, anti-virulence agents, monoclonal antibodies, and microbiome-modulating approaches [93]. Concurrently, policy-oriented research should rigorously evaluate economic incentive models such as subscription-based reimbursement and delinkage mechanisms that decouple antibiotic revenue from sales volume, thereby aligning innovation with stewardship principles [94].
The integration of behavioral and social sciences into AR research has emerged as a critical frontier. Prescribing behavior is influenced by cognitive biases, institutional culture, patient expectations, and perceived clinical risk [95]. Future studies should assess behavioral interventions including audit and feedback, peer comparison, decision-support nudges, and shared decision-making tools to improve prescribing practices across both hospital and community settings. Public engagement strategies aimed at improving antibiotic literacy and reducing demand-driven misuse also require robust evaluation [96].
Enhanced surveillance and data integration represent foundational pillars for future AR control. Research priorities include strengthening national and global surveillance systems, expanding the use of genomic epidemiology, and integrating antimicrobial consumption data with resistance trends in real time [97]. Such data-driven frameworks can support early outbreak detection, inform local treatment guidelines, and improve policy responsiveness.
Finally, future research must explicitly address equity and global disparities in antibiotic resistance. Resistant infections disproportionately affect vulnerable populations, particularly in LMICs, where access to diagnostics, effective antibiotics, and stewardship expertise remains limited [98]. Strengthening pharmacist-led interventions, capacity-building initiatives, and community-based stewardship models should be prioritized to ensure equitable and sustainable resistance containment. In summary, future directions in antibiotic resistance research must be interdisciplinary, implementation-focused, and equity-driven. Aligning innovation with health system realities and human behavior will be essential to preserving antibiotic effectiveness and protecting patient and public health in the coming decades [99].
CONCLUSION:
The antibiotic resistance crisis represents one of the most complex and urgent challenges confronting modern medicine, driven by intricate microbial mechanisms, accelerating evolutionary pressures, and global patterns of antimicrobial misuse. As highlighted in this review, emerging trends, including precision antimicrobials, artificial intelligence–enabled diagnostics, and innovative non-traditional therapies signal a paradigm shift from empirical antibiotic use toward targeted and sustainable interventions. However, technological advances alone are insufficient without robust systems to guide their responsible application. Antimicrobial stewardship programs stand at the core of this effort, translating scientific knowledge into optimized clinical practice, while clinical pharmacists serve as critical catalysts by bridging microbiological evidence, therapeutic decision-making, and patient-centered care. Together, stewardship frameworks and pharmacist-led interventions not only improve individual patient outcomes but also safeguard antimicrobial efficacy at the population level. Looking ahead, the convergence of scientific innovation, policy commitment, and interdisciplinary collaboration will determine whether humanity can outpace bacterial evolution and secure an effective antimicrobial arsenal for generations to come.
REFERENCES
Ettem Ajay, Exploring the Antibiotic Resistance Crisis: Mechanisms, Emerging Trends, and the Transformative Impact of Antimicrobial Stewardship and Clinical Pharmacists on Patient and Public Health, Int. J. of Pharm. Sci., 2026, Vol 4, Issue 3, 2893-2917. https://doi.org/10.5281/zenodo.19199123
10.5281/zenodo.19199123